Gilead Sciences, Inc.
COMBINATION THERAPY COMPRISING AN ACC INHIBITOR
Last updated:
Abstract:
The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.
Status:
Application
Type:
Utility
Filling date:
17 Mar 2021
Issue date:
7 Oct 2021